JAC Advance Access published online on June 4, 2007
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkm182
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Detection of HSV-1 variants highly resistant to the helicase–primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1
1 Department of Veterinary Science, University of Cambridge, Madingley Road, Cambridge CB3 0ES, UK 2 Division of Virology, Department of Pathology, University of Cambridge, Laboratories Block Level 5, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK
Received 2 February 2007; returned 12 March 2007; revised 21 March 2007; accepted 1 May 2007
* Corresponding author. E-mail: hjf10{at}cam.ac.uk
Objectives: BAY 57-1293 is a helicase–primase inhibitor (HPI) from a new class of antivirals that are highly efficacious in herpes simplex virus (HSV)-1 animal infection models. Resistant mutants with point mutations in the helicase (UL5) were reported to be present in laboratory isolates at a low frequency of approximately 10–6. In contrast, we have shown elsewhere that some laboratory isolates contain resistant variants at higher frequency (10–4). Therefore, we screened 10 recent clinical isolates of HSV-1 for BAY 57-1293-resistant virions.
Methods: Clinical isolates were screened by a plaque reduction assay in Vero cells to determine the frequency of occurrence of BAY 57-1293-resistant variants. The helicase gene for the resistant variants was sequenced.
Results: One isolate contained highly resistant variants at 10–4 and another at 10–5. Both variants contained a previously reported BAY 57-1293 resistance mutation (K356N) in UL5 and were >5000-fold resistant.
Conclusions: Occurrence of HPI-resistant viruses at high frequency in a clinical isolate is intriguing. Two alternative hypotheses are proposed to explain this phenomenon. It is also surprising that two unrelated clinical isolates contain an identical HPI resistance mutation. These results have important implications for HPI drug-resistance monitoring during subsequent clinical trials.
Key Words: HSV , antivirals , resistance
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Biswas, R. N. Miguel, S. Sukla, and H. J. Field A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure J. Gen. Virol., August 1, 2009; 90(8): 1937 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Biswas, G. Kleymann, M. Swift, L. S. Tiley, J. Lyall, J. Aguirre-Hernandez, and H. J. Field A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target J. Antimicrob. Chemother., May 1, 2008; 61(5): 1044 - 1047. [Abstract] [Full Text] [PDF]
|
|